echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > CStone Pharmaceuticals announces joint development of loratinib with Pfizer in ROS1-positive advanced lung cancer

    CStone Pharmaceuticals announces joint development of loratinib with Pfizer in ROS1-positive advanced lung cancer

    • Last Update: 2021-06-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    On June 15th, CStone Pharmaceuticals announced that it would cooperate with Pfizer on ROS1-positive advanced non-small cell lung cancer (NSCLC) in Greater China to jointly develop lorlatinib
    .
    This upcoming clinical study of ROS1-positive lung cancer in China is the world's first key study of loratinib on this target

    .
    This is the further deepening of the cooperation between CStone Pharmaceuticals and Pfizer last year after reaching a strategic cooperation

    .

    In recent years, the incidence of lung cancer in China has continued to increase
    .
    According to the latest global cancer burden data in 2020, there will be approximately 820,000 new lung cancer cases in China in 2020, and approximately 710,000 lung cancer deaths

    .
    As a new and unique molecular subtype representative, ROS1 rearrangement is an important lung cancer-related driver gene, which is more common in young, non-smokers or light-smokers with lung adenocarcinoma

    .
    At present, only one targeted drug has been approved for the treatment of ROS1-positive lung cancer patients in China, and new treatment options are still urgently needed for patients with drug resistance

    .

    Loratinib is a third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI) with central nervous system penetration
    .
    As early as November 2018, it was approved by the FDA for accelerated listing in the United States for the second-line treatment of ALK-positive metastatic NSCLC patients who have previously received crizotinib and at least one other ALK inhibitor

    .
    And on March 5 this year, the second indication was approved for the first-line treatment of ALK-positive NSCLC

    .
    Pfizer has also carried out a number of clinical studies of loratinib for ALK-positive lung cancer in China, and submitted a new drug application for ALK-positive advanced NSCLC in March 2021

    .

    In clinical studies, loratinib has also shown preliminary efficacy and good safety for ROS1-positive advanced NSCLC
    .
    In a phase I/II study, loratinib improved the objective response rate (ORR) and intracranial ORR in patients with ROS1-positive advanced NSCLC who were initially treated with TKI drugs or failed ROS1 inhibitor treatment

    .
    For patients with positive brain metastases, loratinib has achieved a higher remission rate and a long-lasting remission time

    .

    Last year, CStone Pharmaceuticals and Pfizer reached a strategic cooperation, including Pfizer’s US$200 million equity investment in CStone Pharmaceuticals, CStone’s authorization of Pfizer to develop and commercialize suggliumab in mainland China, and CStone Pharmaceuticals Introduce more oncology products into the framework of cooperation with Pfizer in the Greater China region
    .
    CStone Pharmaceuticals and Pfizer will jointly select oncology products in the Pfizer pipeline that are in the late stage of research and development (that have passed the proof-of-concept) and jointly develop them in the Greater China region.
    CStone and Pfizer can also optionally cooperate in the Greater China region.
    Introduce other tumor products

    .

    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.